Silver-coated chest tube shows promise for cancer fluid relief
NCT ID NCT02649894
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new type of chest tube coated with silver nitrate against a standard tube for people with recurrent fluid buildup in the chest due to cancer. The goal was to see if the coated tube could seal the space and prevent fluid from coming back more effectively. 119 adults with symptomatic malignant pleural effusion took part. The main measure was how many people achieved pleurodesis (lung sealing) without recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
silver nitrate-coated indwelling pleural catheter
What this could lead to
If it works, this could offer a more effective way to control fluid buildup in the chest for people with cancer, reducing the need for repeat procedures.
What could go wrong
This is a small, completed study (119 people) comparing a coated catheter to an approved one. The coating may not provide significant benefit, and there is a risk of infection or other complications from the device.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT PLEURAL EFFUSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deconess Medical Center West
Boston, Massachusetts, 02215, United States
-
Duke University
Durham, North Carolina, 27710, United States
-
Great Western Hospital
Swindon, United Kingdom
-
Heart Center Research
Huntsville, Alabama, 35801, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Northwestern Unversity
Chicago, Illinois, 60611, United States
-
Oxford Center for Respiratory Medicine, Churchill Hospital
Oxford, United Kingdom
-
SUNY Upstate Hospital
Syracuse, New York, 13210, United States
-
Southmead Hospital
Bristol, United Kingdom
-
St. Vincent Medical Group
Indianapolis, Indiana, 46260, United States
-
Stanford University School of Medicine/ Stanford Cancer Institute
Stanford, California, 94305, United States
-
UNC Hospital
Chapel Hill, North Carolina, 27599, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of Texas, MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Vanderbuilt University
Nashville, Tennessee, 37232, United States
-
Washington Universtiy School of Medicine, Barnes Jewish Hospital
St Louis, Missouri, 63110, United States